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ABSTRACT: The fosfomycin resistance protein, FosX, catalyzes the hydration of the antibiotic fosfomycin,
(1R,2S)-epoxypropylphosphonic acid. Genes encoding the enzyme are found in several pathogenic
microorganisms. The structure and mechanism of action of the genomically encoded FosX enzyme from
Listeria monocytogenes (FosXLMATCC) obtained from the American Type Culture Collection are reported.
The gene harbors 31 point mutations, and as a consequence, the protein differs in 10 amino acid residues
from the previously reported FosX encoded in the genome of the EGD strain of L. monocytogenes
(FosXLMEGD). The FosXLMATCC enzyme is shown to catalyze the addition of water to the C1 position of
the antibiotic with inversion of configuration at C1. The reaction involves Mn(II) activation of the oxirane
oxygen and E44 acting as a general base. The structure of the enzyme has been determined from six
different crystal forms of the protein. The structures of the enzyme without metal bound are similar but
differ in the loop regions. Perhaps the most informative structure is the one with the product bound. This
structure shows that the phosphonate group of the product is bound in an orientation that is different than
that of fosfomycin bound to the related enzyme, FosA. The implication is that the substrate may also be
bound in a different orientation in FosX. A high-resolution structure (1.44 Å resolution) of the enzyme
reveals a unique conformation in which the C-terminal tail of the protein coordinates to the Mn(II) center
via the carboxylate of E126. The kinetic characterization of the E126Q mutant indicates that this
conformation of the protein is probably not relevant to the function of the enzyme. Kinetic analysis of
mutants of active site residue E44 is consistent with its proposed roll as a general base catalyst in the
addition of water to the antibiotic.

Antibiotic resistance in pathogenic microorganisms is an
ever-increasing problem worldwide where bacterial resistance
to many of the “last resort” antibiotics has been observed in
recent years (1). Antimicrobial resistance is often the result
of the selective pressure on microbial populations resulting
from the use or overuse of antibiotics. Three of the most
common bacterial defenses against antibiotics include the
alteration of the antibiotic transport or uptake mechanism,
mutation of the antibiotic target, or inactivation or sequestration of the antibiotic by resistance proteins (1). All three of
these defense mechanisms have been observed with respect
to the natural product fosfomycin 1 (Scheme 1).
†
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Scheme 1

The antimicrobial properties of fosfomycin were first
reported by Merck in 1969 where the molecule was shown
to be effective against both Gram-positive and Gram-negative
bacteria (2-4). Fosfomycin inhibits the enzyme UDP-Nacetylglucosamine-3-enolpyruvyltransferase (MurA),1 which
catalyzes the first committed step in bacterial cell wall
biosynthesis. Later studies determined that fosfomycin ir-
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genomically encoded L. monocytogenes FosX mutant (FosXLMATCC). Extensive structural characterization of this mutant
resulted in identification of a unique conformation of the
C-terminal tail and provides evidence that fosfomycin may
bind to FosX enzymes in an orientation different from that
observed in the FosA proteins (18). Several site-specific
mutants are characterized kinetically so the roles of key
residues in the catalytic mechanism could be probed.
EXPERIMENTAL PROCEDURES

reversibly inactivates MurA by alkylating an active site
cysteine residue (5-7). Upon introduction into the clinic,
resistance to fosfomycin emerged rapidly and was attributed
to mutations affecting antibiotic transport (8, 9) and to
mutations in the MurA target itself (10).
Several years later, a new mechanism of fosfomycin
resistance was identified and linked to a plasmid obtained
from clinical isolates (11). This plasmid contained a gene
encoding a resistance protein (FosA), which catalyzes the
addition of glutathione to the antibiotic (Scheme 1), rendering
it inactive (12, 13). Extensive characterization of this enzyme
demonstrated that it is a Mn(II)-dependent glutathione
transferase (14) that exhibits an enhanced activity in the
presence of monovalent cations (15). A FosA homologue
from Bacillus subtilus (FosB) also acts as a thioltransferase
enzyme catalyzing the Mg2+-dependent addition of L-cysteine
to the epoxide ring of fosfomycin (Scheme 1) (16). Mining
the microbial genome database with the sequences of FosA
and FosB identified a new class of fosfomycin resistance
proteins called FosX (17).
The FosX enzymes catalyze the hydration of fosfomycin
(Scheme 1) in generating the vicinal diol 4. Genes encoding
FosX homologues have been identified in Mesorhizobium
loti, Desulfitobacterium hafniense, and pathogens Listeria
monocytogenes, Brucella melitensis, and Clostridium botulinum. Studies of the FosX enzymes from M. loti (FosXML)
and L. monocytogenes (FosXLM) demonstrated that the
addition of a solvent-derived oxygen occurs in a regiospecific
manner at C1 of fosfomycin (17), but the stereochemical
course of the reaction has remained undefined. The crystal
structure of the FosXML enzyme (17) provided some insight
into the catalytic mechanism but also left many unanswered
questions regarding its modest catalytic activity when
compared to that of FosXLM from L. monocytogenes.
Determination of the structure of the FosXLM could elucidate
the molecular bases for these differences.
In this paper, we present the assignment of the absolute
configuration of the C1 center of the FosX product and the
identification and characterization of a naturally occurring
1
Abbreviations: MurA, UDP-N-acetylglucosamine-3-enolpyruvyltransferase; HEPES, 4-(3-hydroxyethyl)piperazine-1-ethanesulfonic
acid; Tris, tris(hydroxymethyl)aminomethane; EDTA, ethylenediaminetetraacetic acid; DTT, dithiothreitol; DEAE, diethylaminoethyl; TMS,
trimethylsilyl; PEG, polyethylene glycol; MIC, minimum inhibitory
concentration; VOC, vicinal oxygen chelate.

Materials. Fosfomycin disodium salt was purchased from
Fluka. The pET20b(+) plasmid and Rosetta(DE3) cells were
from Novagen (Madison, WI). Phenylboronic acid, HEPES
(free acid), and D2O (99.99 at. % D) were from Aldrich.
N,O-Bis(trimethylsilyl)acetamide (BSA) and trimethylchlorosilane were from Pierce (Rockford, IL). Puratronic grade
MnCl2 was obtained from Alfa Aesar (Ward Hill, MA). The
oligonucleotide primers used for cloning and mutagenesis
were obtained from Invitrogen (Carlsbad, CA). All other
chemicals were reagent grade or better and obtained from
commercial sources.
Cloning, Expression, and Purification of the Fosfomycin
Resistance Protein from L. monocytogenes. L. monocytogenes
genomic DNA (19115D) was obtained from American Type
Culture Collection (Manassas, VA). The lmo1702 gene was
amplified from genomic DNA, via PCR, using synthetic
oligonucleotide primers: forward, 5′-AT AGT ATA CAT
ATG ATT TCA GGA TTA AGC CAT ATC AC-3′; and
reverse, 5′-AAA TTT GGA TCC CTA TTC GTG ATA CCT
TTT CAG C-3′. The primers were designed to incorporate
5′ NdeI and 3′ BamHI restriction sites. After amplification,
the PCR product was purified using the QiaQuick PCR
purification kit (Qiagen Inc., Valencia, CA). The PCR
product and pET20b(+) DNA were doubly digested with
the indicated restriction enzymes, and the digestion products
were gel purified and subsequently ligated to form the
lmo1702ATCC:pET20b(+) expression plasmid. lmo1702
was overexpressed in Escherichia coli Rosetta(DE3) cells
in the following manner. Typically, cells from an overnight
culture, grown in LB medium containing ampicillin (70 µg/
mL) and chloramphenicol (14 µg/mL), were used to inoculate
individual 1.5 L cultures of the same medium. The cells were
grown at 30 °C and 225 rpm. When an OD600 of 0.5-0.7
was reached, the cells were induced by the addition of lactose
(final concentration of 6 mM). The culture was incubated
for an additional 6 h at 30 °C, and the cells were harvested
by centrifugation and stored frozen at -80 °C.
The cell pellet from 3 L of liquid culture was thawed on
ice and resuspended in 25 mL of buffer A [25 mM Tris and
75 mM NaCl (pH 7.5)] containing 0.1 mg/mL lysozyme.
The cell suspension was incubated at 25 °C for 15 min
followed by incubation on ice for 15 min. An additional 60
mL of buffer A was added to the cell suspension, and the
cells were lysed by sonication on ice. The lysate was then
centrifuged (25000g for 30 min) to remove the cell debris.
The supernatant was treated with streptomycin sulfate (1%,
w/v) and centrifuged (30000g for 30 min). The resulting
supernatant was dialyzed against 2 L of buffer A containing
250 mM EDTA and 1 mM DTT. The dialysate was applied
to a 2.5 cm × 12 cm DEAE-cellulose column (Whatman,
Maidstone, U.K.), and the column was developed with a
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linear 75 to 400 mM NaCl gradient. Fractions containing
FosXLMATCC were pooled and dialyzed against 30 mM KH2PO4 (pH 7.0) containing 1 mM DTT. The dialysate was then
loaded onto a 1.5 cm × 8 cm hydroxyapatite column, and
FosXLMATCC was found in the flow-through fractions. The
protein was dialyzed against buffer B [25 mM HEPES (pH
7.5)] containing 100 mM NaCl, 5 mM EDTA, 1 mM DTT,
and 3 g of Chelex 100 to generate a metal-free protein
solution. The dialysate was concentrated to 10 mg/mL and
applied to a 1.6 cm × 60 cm Sephacryl S-100 column that
had been equilibrated in buffer B containing 100 mM NaCl
and 0.5 mM EDTA. Extensive dialysis against buffer B
containing 1 mM DTT and Chelex 100 resin yielded pure
metal-free protein. The protein was concentrated and stored
frozen at -80 °C.
Generation of the Diol Product 4. Fosfomycin (1.5 g) was
dissolved in 15 mL of H2O, and the pH was adjusted to 7.5
via addition of HCl. MnCl2 was added to the fosfomycin
solution to a final concentration of 50 µM. The reaction was
then initiated by the addition of FosXLMATCC (final concentration of 10 µM) and allowed to proceed at room temperature.
The conversion of fosfomycin to the diol product was
monitored by quenching a 500 µL aliquot of the reaction
mixture by vortexing after the addition of 40 µL of CHCl3.
The aqueous layer after centrifugation was then demetalated
by incubation with 50 mg of Chelex 100 for several hours.
The Chelex 100 resin was removed by centrifugation, and
400 µL of the solution was combined with 100 µL of D2O
(99.9 at. % D) and a 1H-decoupled 31P NMR spectrum
acquired. The reaction was considered complete when
fosfomycin could no longer be detected by 31P NMR.
Fosfomycin: 31P NMR (121.495 MHz, D2O) δ 11.16 (s).
1,2-Dihydroxypropylphosphonic acid: 31P NMR (121.495
MHz, D2O) δ 16.95 (s).
When the enzyme-catalyzed reaction was complete, the
enzyme was denatured by vortexing after the addition of 0.5
mL of CHCl3. The aqueous layer after centrifugation was
incubated with 500 mg of Chelex 100 resin for several hours
to remove the Mn(II). The Chelex resin was removed by
centrifugation, and the 1,2-dihydroxypropylphosphonic acid
was taken to dryness by lyophilization.
Determination of the Absolute Configuration at C1 of the
Reaction Product. The generation of the boronate ester of
the FosX product was based upon the method of Islam et al.
(19). A stock solution of phenylboronic acid was prepared
by solubilizing the acid in H2O after titrating the solution to
pH 8.5 with NaOH; 1.2 molar equiv of phenylboronic acid
was added to a 150 mM solution of the diol product (4),
and the final pH was adjusted to 8.5 by addition of NaOH.
The reaction was allowed to proceed at room temperature
for 30 min and then the mixture taken to dryness by vacuum
centrifugation. The dried sample was then dissolved in D2O
(99.96 at. % D), and the phenylboronate ester complex was
characterized by 1H, 13C, 31P, and NOESY NMR spectroscopy: 1H NMR (300.13 MHz, D2O, pD 8.9) δ 1.15 (d, 3H,
J ) 6.3 Hz), 3.37 (s, 1H), 4.03 (s, 1H), 7.29 (m, 3H), 7.6
(d, 2H, J ) 7.4 Hz); 13C NMR (75.471 MHz, D2O) δ 18.76
(d, J ) 8.4 Hz), 68.37 (s), 73.40 (d, J ) 140 Hz), 127.62
(s), 127.90 (s), 132.29 (s); 31P NMR (121.495 MHz, D2O) δ
16.95 (s).
Steady State Kinetics of FosX. The kinetic assays were
conducted either by gas chromatography and mass spec-
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trometry (GC-MS) on a ThermoFinnigan DSQ GC-MS
system with n-butylphosphonate as an internal standard as
previously described (20) or by gas chromatography with
flame ionization detection as described below. Kinetic assays
were conducted at 25 °C in 1 mL of 25 mM HEPES (pH
7.5) containing 100 µM MnCl2. Enzyme (0.5-8 µM) was
preincubated in the reaction buffer for 5 min. Reactions were
initiated by the addition of fosfomycin (0.5-15 mM). After
10 min, the reactions were quenched by the addition of 50
µL of chloroform, and the mixtures were vortexed and
immediately placed on dry ice. The samples were then
thawed, and tert-butylphosphonic acid was added as an
internal standard at a final concentration of 8.1 mM. After
centrifugation at 13000g for 5 min, 200 µL of the samples
was placed in silanized glass tubes and taken to dryness via
a speed vac. The dried samples were derivatized by the
addition of 50 µL of a 1:1:0.2 mixture of chloroform, bis(trimethylsilyl)acetamide, and trimethylchlorosilane. The
tubes were then sealed and incubated at room temperature
overnight. The samples were then injected onto a 0.25 mm
(inside diameter) × 30 m RTX-1701 column attached to a
Clarius 500 gas chromatograph equipped with a flame
ionization detector. A linear temperature gradient (from 145
to 210 °C, at a rate of 5 °C/min) at a constant carrier gas
(He) flow rate of 1 cm3/min was used to elute the samples.
The TMS derivatives of tert-butylphosphonic acid, fosfomycin, and 1,2-dihydroxypropylphosphonic acid eluted at
5.8, 8.5, and 13.3 min, respectively. The concentration of
product was determined using a plot of the area ratio of
product to internal standard versus product concentration.
Generation of the E126Q Mutant of FosXLMATCC. Sitedirected mutagenesis was performed on the lmo1702ATCC:
pET20b(+) expression vector using the QuickChange sitedirectedmutagenesiskit(Stratagene,LaJolla,CA).Oligonucleotide
primers were designed to change codon 126 from GAA to
CAG. The mutant expression plasmid was designated
lmo1702ATCC(E126Q):pET20b(+). The mutation was confirmed by DNA sequencing, and the mutant protein was
expressed and purified as previously described.
Protein Crystallization. The protein readily crystallizes in
a variety of crystal forms depending on the pH and
composition of the crystallization buffer. All crystallization
experiments were conducted at 22 °C by the hanging-drop
vapor-diffusion method. The details for the six crystal forms
are as follows. For the monoclinic crystal (forms I and II),
crystals were grown by mixing 1 µL of the enzyme at 15.0
mg/mL with 1 µL of the reservoir solution [18-20% (w/v)
polyethylene glycol 8000 and 0.1 M sodium citrate (pH 5.75)
for form I or (pH 6.5) for form II, 4-12 mM sodium acetate
and 10% glycerol]. For the hexagonal crystal form, crystals
were obtained after mixing equal volumes of enzyme at 15
mg/mL and the reservoir solution [15% (w/v) polyethylene
glycol 8000, 0.1 M sodium citrate (pH 5.6), and 20 mM
sodium acetate]. For the tetragonal crystal form, crystals were
obtained after mixing equal volumes of enzyme at 15 mg/
mL incubated with 12 mM MnCl2 and the reservoir solution
[22% PEG 3350, 0.1 M Tris (pH 8.1), 0.2 M MgCl2, and
5% 2-propanol]. For the FosX‚Mn(II)‚SO42- complex,
crystals of the complex were obtained after mixing equal
volumes of enzyme at 15 mg/mL incubated with 12 mM
MnCl2 and the reservoir solution [30% PEG 8000, 50 mM
sodium cacodylate (pH 6.5), and 0.1 M ammonium sulfate].
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Table 1: Data Collection, Phasing, and Refinement Statisticsa
PDB entry
wavelength (Å)
resolution (Å)
space group
cell dimensions
a (Å)
b (Å)
c (Å)
R (deg)
β (deg)
γ (deg)
no. of molecules in the asymmetric unit
no. of unique reflections
Rsymb (%)
completeness (%)
redundancy
I/σ(I)
resolution range (Å)
no. of reflections used in refinement
σ cutoff used in refinement
R/Rfreed (%)
no. of refined atoms
protein
heterogen atoms
water
average B-factor (Å2)
rms deviation
bonds (Å)
angles (deg)
Ramachandran statistics
most favored regions (%)
disallowed regions (%)

FosX‚Mn(II)‚SO42-

FosX‚MN(II)‚diol

2P7O
1.5418
1.44
P43

2P7P
1.5418
2.17
C2

2P7Q
1.5418
2.4
C2

68.58
68.58
56.84
90
90
90
2
41281
4.8 (47.8)
86.5 (97.6)
4.6
24.4 (2.1)

169.50
70.57
84.15
90
113.74
90
6
46644
7.9 (46.1)
97.1 (85.8)
3.1
14.7 (2.1)

169.01
69.48
83.97
90
113.86
90
6
33007
8.8 (50.6)
72.6 (45.7)c
2.8
11.9 (1.9)

Refinement Statistics
30-1.85
15-3.3
60303
5815
none
none
23.88/26.77
22.80/27.66

20-1.44
39751
none
12.44/16.69

30-2.17
38493
none
22.57/27.00

30-2.4
28181
none
21.02/27.06

6201
6
96
53.2

6193
0
271
43.7

1908
26
6
30.3

2083
2
168
27.5

6279
36
200
38.9

6209
60
91
46.3

0.007
1.2

0.005
1.2

0.011
1.244

0.012
0.034

0.007
1.3

0.007
1.2

89.8
0.0

91.7
0.0

84.3
0.0

89.4
0.0

89.8
0.0

87.5
0.0

monoclinic I

monoclinic II

hexagonal

2P7L
1.5418
2.2
C2

2P7M
1.5418
1.85
C2

2P7K
1.069
3.3
P61

168.78
70.70
86.97
90
113.98
90
6
44743
4.5 (45.8)
95.5 (73.4)
3.2
23.1 (2.2)

169.43
69.69
84.87
90
113.98
90
6
68258
3.8 (45.7)
88.4 (60.8)
2.6
23.1 (1.8)

83.52
83.52
114.45
90
90
120
2
6813
9.9 (44.0)
99.4 (99.9)
4.5
6.83 (1.3)

27.7-2.2
39011
none
22.99/26.83

tetragonal

a
Values in parentheses are for the highest-resolution shell. b Rsym ) ∑|Ii - 〈I〉|/∑Ii, where Ii is the intensity of the ith observation and 〈I〉 is the
mean intensity of the reflection. c This data set is 72.6% complete due to the fact that the crystal was highly mosaic, resulting in the rejection of
a significant number of reflections during scaling (vida supra). d R ) ∑||Fo| - ||Fc||/∑|Fo|, where Fo and Fc are the observed and calculated
structure factor amplitudes, respectively. Rfree is calculated using 4.9, 3.8, 4.8, 3.8, 3.5, and 3.5% of reflections omitted from the refinement for the
monoclinic I, monoclinic II, hexagonal, tetragonal, FosX‚Mn(II)‚SO42-, and FosX‚Mn(II)‚diol data sets, respectively. The same Rfree set from the
monoclinic form II was used for the refinement of all monoclinic data sets because of their isomorphous character.

For the FosX(E126Q)‚Mn(II)‚diol complex, crystals of the
product complex were obtained with the E126Q mutant
protein by mixing equal volumes of enzyme at 15 mg/mL
containing 12 mM MnCl2, 12 mM diol, and the reservoir
solution [18% PEG 8000, 0.1 M sodium cacodylate (pH 6.5),
0.2 M magnesium acetate, and 10% glycerol].
Data Collection. Diffraction data of the hexagonal crystal
form were collected at 100 K at the PX station at the Center
for Advanced Microstructures and Devices at Louisiana State
University with a MAR charge-coupled device camera. Data
for all other crystal forms were collected at 100 K with a
cryo-stream cooler from Oxford Cryosystems with a 345 mm
MAR Research imaging plate detector mounted on a NONIUS FR591 rotating anode generator (Cu KR radiation). Data
were processed with DENZO and scaled using Scalepack
(21). Data collection and data processing statistics are given
in Table 1.
Crystal Structure Determination. The structure of the
hexagonal crystal form was determined by the molecular
replacement (MR) procedure as implemented in AMORE
(22). A dimer of M. loti FosX (PDB entry 1R9C), its
sequence being 56% identical to that of the target protein,
was used as a search model. MR solutions for all other crystal
structures were located by using the refined structure of the
hexagonal form of the protein. The positioned MR models

were refined using the maximum likelihood refinement in
REFMAC (22) (hexagonal form), SHELX (tetragonal form),
or CNS (23) (all monoclinic data sets). Bulk solvent
correction was applied in each case, and strict NCS constraints were applied for the low-resolution hexagonal form.
In all other crystal structures, no NCS constraints were used
due to the high resolution of the data and significant
differences between conformations of independent molecules.
O (24) was used to build the initial models, as well as
throughout the refinement. Refinement statistics are given
in Table 1. Details of refinement of each particular structure
follow.
Monoclinic Form I (2.2 Å resolution). The asymmetric
unit, as in all monoclinic Listeria FosX crystal forms, is
comprised of three dimers. No significant electron density
was observed for residues 35-39 and 131-133 of monomer
A, 97-102, 132, and 133 of monomer B, 130-133 of
monomer C, 35-41 of monomer D, and 131-133 of both
monomers E and F, an indication that these regions are highly
mobile or disordered. Electron density in the Fo - Fc map
which can be attributed to a glycerol molecule was found in
the active site of monomer A; 96 water molecules were built
into the electron density proximal to hydrogen bonding
partners. Alternate conformations were identified for residues
N24 (monomer C) and C55 (monomer E).
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Monoclinic Form II (1.85 Å resolution). The final model
consists of residues 1-34 and 39-131 (molecule A), 1-94
and 103-130 (molecule B), 1-129 (molecule C), 1-36 and
43-131 (molecule D), 1-128 (molecule E), and 1-130
(molecule F) and 271 water molecules. Alternate conformations were built for E29 and C55 (molecule B), C55
(molecule C), K13 and C55 (molecule D), C55 (molecule
E), and C55 (molecule F).
Hexagonal Form (3.3 Å resolution). The final model
consists of residues 1-33 and 41-128 of both monomers
and six water molecules. A difference Fourier map suggested
the presence of a citrate molecule in the active site of the
protein. No electron density was found that could be
associated with the presence of Mn(II).
Tetragonal Form (1.44 Å resolution). This crystal form
was merohedrally twinned with an almost perfect twinning
fraction of 0.498. The asymmetric unit is comprised of one
dimer. The structure was anisotropically refined due to the
high-resolution data. There is no electron density for residues
A33-A37, A133, B33-B37, B132, and B133. Difference
electron density confirmed that the active site of the protein
contains Mn(II). One hundred sixty-eight water molecules
were located. Residues A24, A43, A56, A78, B24, B27, and
B56 were modeled in two alternate conformations.
FosX‚Mn(II)‚SO42- Complex (2.17 Å resolution). The final
model consists of residues 1-131 (monomer A), 1-95 and
103-129 (monomer B), 1-131 (monomer C), 1-34 and
42-132 (monomer D), 1-131 (monomer E), and 1-131
(monomer F), six Mn2+ cations, six sulfate ions, and 200
water molecules. The C55 residues (monomers C-F) were
modeled in two alternate conformations.
FosX(E126Q)‚Mn(II)‚Diol Complex (2.4 Å resolution).
Two data sets were collected: one to 2.8 Å resolution with
97% completeness and a second one to 2.4 Å with 72.6%
completeness. Difference Fourier from both data sets clearly
established the position and orientation of the diol in the
active site. Full refinement was performed with the higherresolution data set since the presence of six copies of the
protein molecule in the asymmetric unit compensates, in part,
for the incompleteness of the 2.4 Å data. The final model
consists of residues 1-130 (monomer A), 1-95 and 103129 (monomer B), 1-100 and 104-129 (monomer C), 1-35
and 42-132 (monomer D), 1-131 (monomer E), and 1-131
(monomer F), six Mn2+ cations, six diol molecules, and 91
water molecules. The diol product of the reaction was
identified in the active site on the basis of strong electron
density in the difference Fourier map. Residue C55 of
monomer E was observed in two alternate conformations.
The refined coordinates for all six structures have been
deposited in the Protein Data Bank with the entries given in
Table 1.
RESULTS
Characterization of a Naturally Occurring Mutant of FosX
from L. monocytogenes. The PCR-based cloning of the
lmo1702 gene from L. monocytogenes genomic DNA
obtained from American Type Culture Collection led to an
unanticipated result. DNA sequencing of the expression
plasmid containing the cloned lmo1702 gene revealed 31
nucleotide differences in the sequence when compared to
the deposited sequence for the same gene from L. monocy-
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Table 2: Steady State Kinetic Parameters for FosX and Its Mutants
enzyme

kcat (s-1)

kcat/KM (M-1 s-1)

FosXLMEGD a

34 ( 2
<0.00004
52 ( 3
51 ( 2
0.094 ( 0.002
0.011 ( 0.004
<0.00004
0.015 ( 0.002

(9 ( 2) × 104
(7 ( 2) × 104
(4.3 ( 0.2) × 104
63 ( 5
0.26 ( 0.2
(5.0 ( 0.6) × 102

E44Ga
FosXLMATCC
E126Q
E44D
E44T
E44A
FosXML a
a

Previously reported by Fillgrove et al. (17).

togenes strain EGD (25) (Figure S1 of the Supporting
Information). Repeated PCR amplifications yielded a gene
containing these same 31 nucleotide mutations. Translational
analysis of this mutant gene indicated that no new stop
codons had been introduced and that the gene still encoded
a 133-amino acid polypeptide. While some of the nucleotide
mutations were silent, others resulted in the following 10
amino acid mutations in the published protein sequence:
T20A, R23Q, E24N, Q37K, Q65R, R73Q, I83T, S88A,
I93M, and E101Q. Hence, this naturally occurring mutant
gene has been named lmo1702ATCC to distinguish it from
the gene from which the published sequence (lmo1702EGD)
was obtained. One unique aspect of the lmo1702ATCC gene
is the fact that it encodes a FosX that is readily crystallized
to produce diffraction quality crystals under a variety of
crystallization conditions. In contrast, the protein encoded
by the lmo1702EGD gene (FosXLMEGD) could not be coaxed
to crystallize under more than 1400 experimental conditions.
Purification and Properties of FosXLMATCC. The expression
of lmo1702ATCC in E. coli BL21(DE3) cells was quite poor.
Codon usage analysis of the lmo1702ATCC gene indicated
that ∼10% were rare codons in E. coli. Utilization of E. coli
Rosetta(DE3) cells dramatically improved protein expression
where typical yields of pure protein were 30-40 mg/L of
culture. The MALDI-MS analysis of the enzyme gave a
molecular mass of 15 568 Da, which is in good agreement
with the calculated mass of 15 570 Da. A survey of divalent
cation activation of the enzyme confirmed that Mn(II) was
still the preferred metal ion (17). The protein, as FosXLMEGD
does, confers robust resistance (MIC > 25 mg/mL) to
fosfomycin in the biological context of E. coli. In the absence
of the enzyme, E. coli is very sensitive to fosfomycin (MIC
< 0.025 mg/mL). The catalytic efficiency of FosXLMATCC is
equivalent to that of FosXLMEGD (17), suggesting that none
of the 10 mutated amino acids has a dramatic effect on
catalysis (Table 2).
Determination of the Stereochemical Configuration at C1
of the Diol Product. The FosX enzymes catalyze the addition
of a solvent-derived oxygen atom to C1 of fosfomycin. The
ring opening reaction preserves the S configuration at C2,
but the configuration at C1 is unclear. The C1 center can
adopt either the R or S configuration, resulting in either of
two possible products, (1S,2S)-4 or (1R,2S)-4 (Scheme 2).
To distinguish between the two possible products generated
by the FosX enzymes, the phenylboronate ester derivative
of the vicinal diol product was prepared and analyzed by
NOESY NMR. The ester should be either 5 or 6 (Scheme
2) depending on the configuration at C1 of 4.
The derivatization reaction was complete within 30 min
of mixing phenylboronic acid with 4 in water at pH 8.5. The
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FIGURE 1: Region from 4.5 to 0.5 ppm of the NOESY 1H NMR
spectrum of the phenylboronic ester of 4. A cross-peak is observed
between the C1 proton resonance at 4.05 ppm and the C3 methyl
proton resonance at 1.15 ppm. The presence of this cross-peak and
the absence of a cross-peak between the C1 proton resonance and
the C2 proton resonance at 3.38 ppm indicate that the C1 center
has the S configuration.
1

H NMR spectrum (Figure 1) confirmed the formation of
the boronate ester complex where the splitting patterns for
the protons on C1 and C2 of the free diol, at 3.38 and 4.05
ppm, respectively (Figure S2 of the Supporting Information),
had collapsed from multiplets to broad singlets due to
coupling to the 10B and 11B nuclei of the ester. The virtue of
using phenylboronic acid to form the boronate ester complex
was that the 1H resonances of the phenyl ring are downfield
from the 1H resonances of the diol moiety, allowing for the
easy assignments of NOEs. The NOESY NMR spectrum of
the boronate ester complex is shown in Figure 1. We
anticipated that a NOE would be observed between the
neighboring C2 and methyl protons for either product
configuration. The presence of a NOE between the C1 proton
and methyl protons in conjunction with the absence of a NOE
between the C1 and C2 protons demonstrates that the
boronate ester is 6 and the FosX diol product is (1S,2S)-4.
The NOESY NMR spectrum of the underivatized diol
exhibits NOEs between both the C1 and C2 protons and
between the C1 and methyl protons as a consequence of free
rotation about the C1-C2 bond (Figure S2 of the Supporting
Information).
Structure of FosXLMATCC with Mn(II) and SO42- Bound.
The structure of FosX (Figure 2) is remarkably similar to
that of FosXML from M. loti (17) and to that of the FosA
enzymes from Pseudomonas aeruginosa (FosAPA) (18) and
from transposon Tn2921 (FosATN) (26). This homodimeric
enzyme is in a domain-swapped arrangement where H7 of
one subunit joins H69 and E118 from the opposite subunit
to form the divalent metal ion-binding site. The average
ligand-metal distances in the six active sites for H7 (2.3
Å), H69 (2.4 Å), E118 (2.2 Å), and the sulfate oxygen (2.2
Å) are reasonable. The hydroxyl group of T9 is within
hydrogen bonding distance of one of the sulfate oxygens (2.8
Å, averaged over all six active sites). The cup-shaped metal-
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FIGURE 2: Ribbon diagram of the FosXLMATCC dimer containing
Mn(II) with the two subunits colored red and teal. The Mn(II) ions
are colored magenta, and the sulfate ions are depicted as sticks.
The image was generated using PYMOL (29).

binding site is formed by paired βRβββ motifs as observed
with other fosfomycin resistance proteins and members of
the VOC superfamily (27, 28). The position of the bound
sulfate ion is of particular interest since it is expected to be
a good indicator of the position of the phosphonate group in
the substrate or product complexes.
Comparison with the Structures of the Apoenzyme. As
was the case with the FosATN enzyme from transposon
Tn2921 (26), the use of citrate buffer and low pH in
crystallization experiments prevents binding of the Mn(II)
cation in the active site of the protein. Varying the pH
of the citrate buffer yielded several apo structures of
FosXLMATCC, including monoclinic form I (pH 5.75) and form
II (pH 6.5) and a hexagonal crystal form (pH 5.6). Both
monoclinic crystal forms are isostructural with three dimers
in the asymmetric unit. Superposition of these structures
indicated that the A-B dimers are quite similar with a 0.534
Å rmsd for 245 equiv CA atoms, while C-D and E-F
dimers exhibit alternate orientations of the loops between
residues 34-43 and 94-103.
Structure of FosX(E126Q) with Bound Product. Crystallization trials with the E126Q mutant of FosXLMATCC in the
presence of the product (1S,2S)-4 resulted in crystals
containing the diol bound in the active site. The structure
was determined at a resolution of 2.4 Å. The electron density
for the product is quite clear (Figure 3A). The chirality of
the diol product observed in the structure agrees with the
stereochemical assignment determined by NMR. The product
binds to the active site with numerous interactions (Figure
3). Primary interactions with the Mn(II) center include one
of the phosphonate oxygens and the C2 OH group of the
product with bond distances averaged over the six active sites
of 2.1 Å for both. The coordination geometry about the metal
is best described as square pyramidal with H69, E118, and
the product in the pyramidal plane and H7 perched in the
apical position (Figure 3B). There are also several potential
hydrogen bonding interactions with the diol (Figure 3C),
although not all interactions are found in every active site.
For example, the C2 OH group is within hydrogen bonding
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FIGURE 3: Active site of FosXLMATCC with the product (1S,2S)-4 bound. (A) Stereoview of the electron density Fo - Fc simulated annealed
omit map at a resolution of 2.4 Å with the omitted product molecule contoured at 4σ. Metal ligands H7, H69′, and E118′ as well as residues
Y108′ and T9 that participate in the binding of the product are shown. (B) Square pyramidal coordination geometry of the metal ion with
H7 in the apical position. The metal-ligand interactions are denoted with solid lines. (C) Composite of the possible hydrogen bonds
observed in the six active sites denoted with dotted lines.

distance (2.9 Å, averaged over five active sites) of the
carboxylate oxygen of E118 that is not coordinated to the
Mn(II). The C2 OH group is also within hydrogen bonding
distance of the side chain OH group of Y108 (2.8 Å averaged
over six active sites). The OH group at C1 of the diol is
within hydrogen bonding distance of the OH groups of both
Y67 (2.7 Å, averaged over four active sites) and Y108 (2.9
Å, averaged over four active sites) and the carboxylate of
E118 that is coordinated to the metal (2.8 Å, averaged over
four active sites). Finally, there is also potential hydrogen
bonding between one of the phosphonate oxygens and the
OH group of T9 (2.9 Å) averaged over six active sites. A
summary of all observed interactions with the product bound
in the active sites is given in Figure 3C.
Identification of an Unusual Conformation of the CTerminal Tail. The high-resolution structure of the tetragonal
crystal form of FosX exhibited a unique orientation of the
C-terminal tail that is not observed in any of the other FosX
structures. While the C-terminal tail is typically a helix that
extends away from the active site, in this structure, the tail
loops back into the active site where a carboxylate oxygen
of E126 directly coordinates with the Mn(II) center at a
distance of 2.15 Å averaged over the two active sites (Figure
4B). The E126 carboxylate is also within hydrogen bonding
distance of the side chain OH group of T9 (Figure 4). A
superposition of this structure with the structure containing
4 shows that the phosphonate of 4 and the carboxylate of
E126 occupy the same space (Figure 4B) where an oxygen
atom from each coordinates to the Mn(II) center. In addition,
a water molecule is also observed bound to the Mn(II) at a
distance of 2.24 Å averaged over the two active sites. The
five-coordinate geometry of the Mn(II) is square pyramidal

and very similar to the geometry of the product complex
with H7 in the apical position (compare Figure 3B with
Figure 4C).
The question of whether this structure represents a
dominant conformation in solution or an artifact imposed
by crystal packing arises. If the protein adopts this conformation in solution to a significant extent, the C-terminal tail
would be expected to inhibit enzyme activity by partially
occupying the fosfomycin binding site. To test this hypothesis, the steady state kinetic parameters of the E126Q mutant
(the mutant used to obtain the structure of the product
complex) were determined (Table 2). It is expected that with
glutamine in position 126, the mutant would have a weaker
tendency to form a complex with the Mn(II) center. Although
there is a small decrease in the kcat/KM for the mutant enzyme
(Table 2), the results indicate that the observed conformation
of the tail in the tetragonal crystal form is probably not the
dominant conformation in solution.
Role of E44 in Catalysis. The previous structural analysis
of the active site structure of FosXML suggested that E44
acts as a general base in the addition of water to the antibiotic
while the Mn(II) center provides electrophilic assistance and
T9 supplies a proton (Figure 5). Indeed, the E44G mutant
of FosXML exhibited a substantially reduced catalytic activity
(17). The same mutation in FosXLMEGD (an enzyme with an
efficiency much higher than that of FosXML) produced a
protein with no detectable activity, suggesting that the mutant
might be structurally compromised and therefore catalytically
defective. In this context, the role of E44 in the reaction was
investigated further. The E44A mutant of FosXLMATCC was
also essentially inactive as a catalyst, a result consistent with
a structurally compromised enzyme. In contrast, the more
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FIGURE 5: Proposed participation of E44 as a general base in the
catalytic mechanism of FosX (17). The distance between the
carboxylate of E44 and C1 of fosfomycin is estimated to be between
5 and 6 Å.2

addition of water to the epoxide. The most conservative
mutation (E44D) exhibits a catalytic efficiency that is reduced
by a factor of ∼1100, a magnitude that is consistent with
E44 acting as a general base in the addition of water.
DISCUSSION

FIGURE 4: (A) Ribbon diagram of the FosX dimer of the tetragonal
crystal form. The two subunits are colored red and blue. The Mn(II) ions are colored purple. The C-terminal tail has adopted an
orientation allowing E126 to coordinate the Mn(II) ion. (B)
Superposition of the high-pH tetragonal crystal form and FosX
structure with the product bound. The superposition was generated
using the positions of T9, the metal ion, and the metal ligands H7,
H69, and E118. The T9 and H69 residues are not shown for clarity.
The tetragonal structure is colored blue, while the structure of FosX
with product bound is colored red. (C) Square pyramidal coordination geometry about the metal with H7 in the apical position.

conservative mutants, E44D and E44T, expressed well, were
isolable and had easily detectable, though much reduced,
catalytic activity (Table 2). These results are consistent with
the proposed role of E44 acting as a general base in the

Mechanism and Stereochemical Course of the FosXCatalyzed Reaction. Previous work has established that the
regiochemistry of the FosX-catalyzed reaction involves
addition of water at C1 of the antibiotic (17). The carboxylate
of E44 is located in a position that is estimated to be ∼5-6
Å from C1 of bound fosfomycin, a location that is consistent
with E44 acting as a general base in the addition of water to
the epoxide (Figure 5). Many microbial and mammalian
epoxide hydrolases use a carboxylate to form an alkylenzyme intermediate that is subsequently hydrolyzed (30).
However, single-turnover experiments with both FosXML and
FosXLMEGD are consistent with the direct addition of water
to the epoxide (17). Analogous to the proposed mechanism
of FosA, the metal ion is presumed to act as an acid catalyst
by interacting with the oxirane oxygen. Acid-catalyzed
hydration of epoxides can occur by direct SN2 addition of
water with inversion of configuration at the oxirane carbon
or via a carbocation intermediate with either mixed stereochemistry or retention of configuration (31). That the FosX
reaction product, 4, is now known to be (1S,2S)-1,2dihydroxypropylphosphonic acid shows that the stereochemical course of the FosX-catalyzed reaction proceeds with
inversion of configuration by direct SN2 attack of an activated
water molecule at C1 of fosfomycin. The observed reaction
mechanism proceeds in a manner similar to that proposed
for FosA where nucleophilic addition occurs R to the
phosphonate with inversion of configuration (32).
Insights into Substrate Binding. The identification of a
naturallyoccurringmutantofthe ListeriaFosX(lmo1702ATCC)
had a major impact on this work. This mutant enzyme
crystallized readily under multiple conditions. Analysis of
the FosX structures reveals that each amino acid mutation
was located either on the surface of the protein or in a region
with high solvent accessibility away from the active site.
Most importantly, the structure of the product complex with
2 The distance of 5.1 Å between the carboxylate of E44 and C1 of
the substrate is based on a model of the substrate complex. The distance
between E44 and C1 of the diol product is 5.9 ( 0.3 Å (averaged over
the six active sites). From these results, we conclude that E44 is
probably between 5 and 6 Å from C1 in the actual substrate complex.
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FIGURE 6: Local superposition of the FosX(E126Q)‚Mn(II)‚4
complex (colored) with the P. aeruginosa FosA‚Mn(II)‚1 complex
(blue). The overlay illustrates the different positions of the
phosphonate groups observed in the FosX and FosA structures. The
potential electrostatic interactions between the K+ ion (blue sphere)
in the FosA structure and the phosphonate of 1 could result in this
difference in binding orientation. The superposition was generated
using the positions of the metal and conserved metal ligands H7,
H69, and E118.

the FosX(E126Q) mutant provided surprising new insight
into how the FosX enzyme might bind the substrate.
The high-resolution structure of FosAPA in the presence
of the substrate 1 provided a detailed look at the interactions
between the protein and the metal and the orientation of the
substrate in the active site (18). Extrapolation of this structure
to that of FosX initially suggested a specific mechanism for
the hydration reaction involving E44 as a general base
(Figure 5) (17). Surprisingly, the structure of the product
complex, FosX‚Mn(II)‚4, indicates that the phosphonate
group is oriented ∼180° from the phosphonate group in the
substrate complex of FosAPA. In contrast to the observed
orientation of fosfomycin bound in the active site of FosAPA
(18), the phosphonate of 4 bound to FosX is oriented away
from the potassium ion in FosA as illustrated in Figure 6.
The close superposition of the Mn(II) ligands for both
structures indicates that the binding of 4 in this new
orientation is not result of an altered Mn(II) binding site.
Additional evidence supporting this unpredicted orientation
of substrate and product binding may be found in the
E‚Mn(II)‚SO42- structure and the structure with the Cterminal tail in the active site. The superposition of the FosX‚
Mn(II)‚4 and FosX‚Mn(II)‚SO42- structures (data not shown)
indicates that the sulfate binds in the same position of the
phosphonate of 4. Likewise, a carboxylate oxygen of El26
is observed coordinating to the Mn(II) center and results in
the carboxylate occupying the same space as the phosphonate
of 4 in the superimposed structures (Figure 4B).
The structural evidence suggests a very strong propensity
for binding an anion (phosphonate) in the FosX enzyme that
is different from the phosphonate orientation observed in the
FosA-fosfomycin complex. The functional implication is
that the substrate is bound in opposite orientations in FosA
and FosX. One possible reason for the difference in orientation is that FosA contains a K+ ion-binding site near the
active site that has been proposed to guide the orientation
of fosfomycin in the substrate complex. The FosX enzymes
have no such binding site and no dependence on monovalent
cations. An alternative, trivial, explanation is that the
preferred orientation of the product in the FosX enzyme
simply does not represent the binding geometry of the
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FIGURE 7: Orientation of E44 with respect to fosfomycin bound
in the opposite orientation in the active site of FosXLM. The distance
between the carboxylate of E44 and C1 of fosfomycin in the
modeled complex is 5.1 Å. Note the difference in the potential role
of T7 in the reaction compared to Figure 5 where the substrate is
bound in the alternate orientation.

substrate. The current experimental evidence cannot strictly
rule out this possibility.
Inasmuch as the role of E44 as a participant in catalysis
was inferred from the orientation of the substrate seen in
the structure of FosAPA, it is fair to ask whether this residue
is in an appropriate position to act as a general base if the
substrate binds in the opposite orientation. A quick modeling
exercise with the substrate and the FosXLMATCC structure
indicates that E44 could play the same role in catalysis in
either orientation as indicated in Figure 7. The carboxylate
is still between 5 and 6 Å from the backside of C1 with
room for a water molecule between it and the substrate.2
However, the hydroxyl group of T9 now serves as an anchor
for the phosphonate rather than for protonation of the oxirane
oxygen as suggested previously in Figure 5.
Comparison of FosXML and FosXLM. The FosXML enzyme
was the first protein described to have fosfomycin hydrolase
activity. However, that activity is quite low (Table 2), and
the protein does not confer significant resistance to fosfomycin in E. coli (MIC e 0.025 mg/mL). The gene encoding
FosXML is located in a phn operon of M. loti, an operon
presumed to be involved in the transport and utilization of
phosphonates. From these observations, we have concluded
that FosXML is not a fosfomycin resistance protein but is an
evolutionarily related protein that plays some yet to be
identified role in the catabolism of phosphonates.
The FosXML and FosXLM proteins are closely related
structurally with a root-mean-square deviation (rmsd) on CA
atoms of 0.789 Å (Figure 8). However, the structural
differences that determine whether one enzyme is a fosfomycin resistance protein are not obvious. The structures of
the active site are virtually identical except for differences
in the loops leading into the metal-binding site. It seems
likely that differences in the loop structures may account, at
least indirectly, for the differences in catalytic efficiency.
Conclusions. The FosX enzyme encoded in the genome
of L. monocytogenes catalyzes the addition of water to the
C1 position of the antibiotic with inversion of configuration.
The results suggest that both the EGD and ATCC strains of
the bacterium have an intrinsic resistance to the antibiotic
provided by the FosX enzyme.
SUPPORTING INFORMATION AVAILABLE
DNA sequence and translation of the lmo1702ATCC gene
(Figure S1) and the NOSEY NMR spectrum of (1S,2S)-1,2dihydroxypropylphosphonic acid, 4 (Figure S2). This material
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FIGURE 8: Global structural superposition of the CA atoms of the
FosXML and FosXLMATCC enzymes. The FosXLMATCC structure used
for the superposition was that of the FosX‚Mn(II)‚SO42-. The
principal differences lie in the loops. The structural superposition
was achieved with CHIMERA (33).

is available free of charge via the Internet at http://
pubs.acs.org.
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